Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 4
2016 2
2017 3
2018 1
2019 2
2020 3
2021 9
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean manila rubin (4 results)?
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?
Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, Faggiano A, Colao A; NIKE; Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferraù F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, Pofi R, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, Zatelli MC. Vitale G, et al. Among authors: rubino m. Rev Endocr Metab Disord. 2021 Sep;22(3):511-525. doi: 10.1007/s11154-020-09589-y. Epub 2020 Sep 15. Rev Endocr Metab Disord. 2021. PMID: 32935263 Free PMC article. Review.
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.
Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, Pusceddu S, Prinzi N, Lombardi Stocchetti B, Grozinsky-Glasberg S, Gross DJ, Walter T, Robelin P, Lombard-Bohas C, Frassoni S, Bagnardi V, Antonuzzo L, Sparano C, Massironi S, Gelsomino F, Bongiovanni A, Ranallo N, Tafuto S, Rossi M, Cives M, Rasul Kakil I, Hamid H, Chirco A, Squadroni M, La Salvia A, Hernando J, Hofland J, Koumarianou A, Boselli S, Tamayo D, Mazzon C, Rubino M, Spada F. Fazio N, et al. Among authors: rubino m. Endocr Relat Cancer. 2023 Apr 26;30(6):e220395. doi: 10.1530/ERC-22-0395. Print 2023 Jun 1. Endocr Relat Cancer. 2023. PMID: 36930250
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N; IEO ENETS Center of Excellence for GEP NETs. Martins D, et al. Among authors: rubino m. Target Oncol. 2017 Oct;12(5):611-622. doi: 10.1007/s11523-017-0506-5. Target Oncol. 2017. PMID: 28634872 Review.
Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
Lambrescu I, Fica S, Martins D, Spada F, Cella C, Bertani E, Rubino M, Gibelli B, Grana C, Bonomo G, Funicelli L, Ravizza D, Pisa E, Zerini D, Ungaro A, Fazio N; IEO ENETS Center of Excellence for GEP NET. Lambrescu I, et al. Among authors: rubino m. Cancer Treat Rev. 2017 Apr;55:46-56. doi: 10.1016/j.ctrv.2017.02.007. Epub 2017 Feb 24. Cancer Treat Rev. 2017. PMID: 28314176 Review.
30 results